Viking, Therapeutics

Viking Therapeutics Stock Surges on Acquisition Speculation

Published on 10/08/2025 at 14:54 | Redaktion boerse-global.de

Market Dynamics Fuel Investor Interest

Viking Therapeutics Stock Surges on Acquisition Speculation Illustration mit AI erstellt übermittelt durch boerse-global.de
Viking Therapeutics Stock Surges on Acquisition Speculation Illustration mit AI erstellt übermittelt durch boerse-global.de

Shares of Viking Therapeutics experienced a dramatic surge yesterday, climbing an impressive 15.1% amid intensified takeover rumors and heightened retail trading activity. The stock price moved from $30.55 to $32.28 while trading volume reached 7.2 million shares, significantly exceeding average levels.

The substantial price movement appears driven by renewed speculation about Viking’s potential as an acquisition target. Market participants pointed to unconfirmed reports suggesting the obesity drug developer has become an attractive candidate for larger pharmaceutical companies seeking expansion. Viking’s established position within the lucrative GLP-1 weight-loss market represents a primary factor behind the acquisition interest.

Recent industry consolidation has further amplified these speculations. Pfizer’s acquisition of Metsera and Roche’s purchase of 89bio have demonstrated the growing appetite among... Read more...

Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.

en | US92686J1060 | VIKING | boerse | 68255846 |